*Please inquire the availability for this product. Kigamicin C was discovered by an anti-austerity strategy, targeting cancer cells' tolerance to starvation. It selectively kills PANC-1 cells (a pancreatic cell line) at concentrations 100 times lower under nutrient starved conditions than in normal conditions. The mechanism of action is proposed to be via blockade of aPKB/Akt activation, caused by the withdrawal of nutrients. It is active in vivo against a human pancreatic cancer xenograft model. Kigamicin C also inhibits the growth of Gram positive bacteria including MRSA, but is not active against Gram negative bacteria.

Additional Information

Product #	K-2023
CAS #	680571-51-1
Formula	C41H47NO16
MW	809.8
Appearance	Pale yellow powder
Purity	>98% by HPLC
Solubility	Soluble in ethanol, methanol, DMSO, and DMF
Storage Temp	-20°C
Therapeutic Area	Oncological Disorders
Use	Kigamicin C and other kigamicins demonstrate cytotoxicity against PANC-1 pancreatic cancer cells

Additional Information

MDL Number	MFCD09954098
InChI	InChI=1S/C41H47NO16/c1-15-20(56-25-12-22(50-4)32(44)16(2)55-25)5-6-24(54-15)57-23-11-19(43)28-35(47)31-36(48)30-26-17(9-18-13-41(3)42(7-8-53-41)40(49)27(18)34(26)46)10-21-29(30)38(52-14-51-21)39(31)58-37(28)33(23)45/h9,15-16,19-25,32-33,43-46,48H,5-8,10-14H2,1-4H3/t15-,16-,19+,20+,21-,22-,23-,24+,25+,32-,33+,41-/m1/s1
SMILES	O=C3N1[C@@](OCC1)(C)Cc2cc5c(c(O)c23)c7c4c(OCO[C@@H]4C5)c6O/C%10=C(\C(=O)c6c7O)[C@@H](O)C[C@@H](O[C@@H]9O[C@H](C)[C@@H](O[C@@H]8O[C@H](C)[C@@H](O)[C@H](OC)C8)CC9)[C@@H]%10O